![](/img/cover-not-exists.png)
Dose Selection for a Direct and Selective Factor IXa Inhibitor and its Complementary Reversal Agent: Translating Pharmacokinetic and Pharmacodynamic Properties of the REG1 System to Clinical Trial Design
T. J. Povsic, M. G. Cohen, M. Y. Chan, S. L. Zelenkofske, W. A. Wargin, R. A. Harrington, J. H. Alexander, C. P. Rusconi, R. C. BeckerVolume:
32
Language:
english
Pages:
11
DOI:
10.1007/s11239-011-0588-3
Date:
July, 2011
File:
PDF, 277 KB
english, 2011